CENTERS FOR HIV/AIDS-RELATED STRUCTURAL BIOLOGY (P50) HARC CENTER: HIV ACCESSORY AND REGULATORY COMPLEXES OVERALL SUMMARY The HARC Center is an integrated program proposed by investigators whose overarching goal is to improve understanding of the interactions between HIV accessory and regulatory proteins and host cellular systems to enable eventual expansion of therapeutic approaches. There are currently no HIV therapeutics targeting any of the proteins on which the HARC Center is focused (HIV-1 Vif, Vpu, Nef, Tat and Rev proteins and their interacting viral and cellular partners). The scientific focus of the Center is on determining structures of these complexes, using an integrated Systems to Structure pipeline that includes (1) Discovery, through novel methods of functional proteomics and genetics being developed in the HARC Center, (2) Validation through breakthrough CRISPR methods in primary T cells as well as targeted in vivo and in vitro functional assays, and (3) Structure Determination using a synthesis of innovative structural techniques developed in the HARC Center to address the large, flexible, heterogeneous and sometimes membrane-associated systems we study. We are focused on two themes aimed at understanding the biological questions surrounding HIV replication and persistence in the host cell. These include how the virus counteracts host restriction mechanisms (Theme 1: ?Counteracting?) and how the virus hijacks host systems for viral transcription and RNA export/trafficking to ensure continuation of the viral life cycle (Theme 2: ?Hijacking?). The seven projects proposed here include: (1) Structure and Evolution of APOBEC3-Vif Interactions, (2) Regulation of Vif and Rewiring of Host Pathways, (3) The Multiple Functions of Vpu at the Membrane, (4) Nef Interaction Networks at the Membrane, (5) Tat-Host Transcription Complexes, (6) Structure and Dynamics of Rev and RNA-Host Complexes, and (7) Characterization of ?Super Restriction Factors? and Prediction of Host-HIV Interfaces. The HARC Center projects are supported by an administrative core and seven technology cores essential for their completion: (1) Proteomic Approaches to HIV Function, (2) CRISPR in Primary Cells to Study HIV-Host Function, (3) Molecular Imaging Using Cryo-Electron Microscopy (EM), (4) Application and Development of Antibody Tools, (5) Integrative Modeling of HIV-Human Complexes, (6) X-ray Screening and Rapid Structure Determination, and (7) Membrane Protein Expression/Purification. We are committed to collaborating with Sister Centers and the HIV research community as well as training the next generation of investigators. We create and support opportunities including the Technology Training Residency to bring young investigators to learn in our Center's Cores, and we seed new research through the Collaborative Opportunity Fund, along with holding events such as seminars and an annual symposium.
The HARC Center mission is to elucidate the molecular basis of systems that are essential for, or contribute to, the pathogenesis of HIV/AIDS, including the physical/functional interactions that occur between viral and human proteins, membranes, lipids and nucleic acids (DNA/RNA). None of the HIV accessory or regulatory proteins are currently targeted by anti-viral therapeutics, and so better molecular understanding of their functions and mechanisms may reveal new therapeutic strategies for intervention, including strategies that may escape the limitations of current drug regimens where mutations in the targeted HIV enzymes can diminish drug efficacy. Through our powerful structure/function pipeline, now expanded to include CRISPR technology and other genetic approaches, we can gain unprecedented insight into HIV biology, new avenues to complex structures, and the potential to fundamentally alter treatment strategies by targeting key cellular processes that contribute to AIDS at interfaces where mutational resistance is highly unlikely.
|Chen, Si-Han; Jang, Gwendolyn M; Hüttenhain, Ruth et al. (2018) CRL4AMBRA1 targets Elongin C for ubiquitination and degradation to modulate CRL5 signaling. EMBO J 37:|
|Leoz, Marie; Kukanja, Petra; Luo, Zeping et al. (2018) HEXIM1-Tat chimera inhibits HIV-1 replication. PLoS Pathog 14:e1007402|
|Cheng, Yifan (2018) Single-particle cryo-EM-How did it get here and where will it go. Science 361:876-880|
|Roth, Theodore L; Puig-Saus, Cristina; Yu, Ruby et al. (2018) Reprogramming human T cell function and specificity with non-viral genome targeting. Nature 559:405-409|
|Ferdin, Jana; Gori?ar, Katja; Dolžan, Vita et al. (2018) Viral protein Nef is detected in plasma of half of HIV-infected adults with undetectable plasma HIV RNA. PLoS One 13:e0191613|
|Cheng, Yifan (2018) Membrane protein structural biology in the era of single particle cryo-EM. Curr Opin Struct Biol 52:58-63|
|Ivry, Sam L; Meyer, Nicole O; Winter, Michael B et al. (2018) Global substrate specificity profiling of post-translational modifying enzymes. Protein Sci 27:584-594|
|Cary, Daniele C; Peterlin, B Matija (2018) Procyanidin trimer C1 reactivates latent HIV as a triple combination therapy with kansui and JQ1. PLoS One 13:e0208055|
|Palovcak, Eugene; Wang, Feng; Zheng, Shawn Q et al. (2018) A simple and robust procedure for preparing graphene-oxide cryo-EM grids. J Struct Biol 204:80-84|
|Tambe, Akshay; East-Seletsky, Alexandra; Knott, Gavin J et al. (2018) RNA Binding and HEPN-Nuclease Activation Are Decoupled in CRISPR-Cas13a. Cell Rep 24:1025-1036|
Showing the most recent 10 out of 199 publications